#3½ 3/7/03

## UNITED STATES PATENT AND TRADEMARK OFFICE

Group Art Unit: 1619

Examiner: Unassigned

in te Patent Application of	
Konradi, et al.	
Application No.: 09/910,431	
Filed: July 19, 2001	
For: Heteroaryl-Beta-Alanine Derivatives as Alpha 4 Integrin Inhibitors	

## INFORMATION DISCLOSURE STATEMENT TRANSMITTAL LETTER

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

Enclosed is an Information Disclosure Statement and accompanying form PTO-1449 for the above-identified patent application.

[x]	No additional fee for submission of an IDS is required.			
[]	The fee of \$180.00 (126) as set forth in 37 C.F.R. § 1.17(p) is also enclosed.			
[]	A certification under 37 C.F.R. § 1.97(e) is also enclosed.			
[ ]	A certification under 37 C.F.R. § 1.97(e), and the fee of \$180.00 (126) as set fort in 37 C.F.R. § 1.17(p) are also enclosed.			
[]	Charge \$ to Deposit Account No. 02-4800 for the fee due.			
[]	A check in the amount of \$ is enclosed for the fee due.			
The Commissioner is hereby authorized to charge any appropriate fees under 37 C F D				

The Commissioner is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

P.O. Box 1404 Alexandria, Virginia 22313-1404 (650) 622-2300

Date: November 20, 2001

Gerald F. Swiss Registration No. 30,113



N THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of	)
Konradi et al.	) Group Art Unit: 1619
Application No.: 09/910,431	) Examiner: Unassigned
Filed: July 19, 2001	)
For: Heteroaryl-Beta-Alanine Derivatives as Alpha 4 Integrin Inhibitors	)
Alpha i mogrii ilmonoto	)

## INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56, Applicants hereby submit the following information in conformance with 37 C.F.R. §§ 1.97 and 1.98.

Pursuant to 37 C.F.R. § 1.98, a copy of each of the documents cited below is enclosed.

## **Articles:**

Abraham, W.M., et. al., J. Clin. Invest., 93, p. 776, (1994)

Berlin, C., et al., Cell, 74, p. 185, (1993)

Binns, R.M., et al., J. Immunology, 157, p. 4094, (1996)

Briskin, M.J., et al., J. Immunol., 156, p. 719, (1996)

Cardarelli, P.M., et al., J. Biol. Chem., 269, p. 18668, (1994)

Berger, E., et al., PNAS, 88, p. 8072, (1991)

Holzmann, B. et al., *EMBO J.*, <u>8</u>, p. 1735, (1989)

Humphries, M. J., et al., Ciba Foundation Symposium, 189, p. 177, (1995)

Issekutz, T.B., J. Immunology, p. 3394, (1992)

Li, Z., et al., Am. J. Physiol, 263, L723, (1992)

Marlin, S., D., et al., J. Exp. Med., 164, p. 855, (1986)

Osborne, L., Cell, 62, p. 3, (1990)

Podolsky, D.K., J. Clin. Invest., 92, p. 373, (1993)

Information Disclosure Statement Application No. <u>09/910,431</u> Attorney's Docket No. <u>002010-684</u> Page 2

Shroff, H.N., Bioorganic. Med. Chem. Lett., 6, p. 2495, (1996)

Sonnenberg, A., Current Topics in Microbiology and Immunology, 184, p. 7, (1993)

Springer, T.A., *Nature*, <u>346</u>, p. 425, (1990)

Springer, T.A., Cell, 76, p. 301, (1994)

Vanderslice, P., J. Immunol., 158, p. 1710, (1997)

Yang, X-D, et al., PNAS, 91, p. 12640, (1994)

Yednock, T.A., et al., Nature, 356, p. 63, (1992)

The documents are being submitted within 3 months of the filing or entry of the national stage of this application or before the first Office Action on the merits, whichever is later, therefore no fee or certification is required under 37 C.F.R. § 1.97(b).

To assist the Examiner, the listed on the attached form PTO-1449. It is respectfully requested that an Examiner initialed copy of this form be returned to the undersigned.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

Garald E Swin

Registration No. 30,113

P.O. Box 1404 Alexandria, Virginia 22313-1404 (650) 622-2300

Date: November 20, 2001